Do you know these drugs for treating ovarian cancer?

Hello everyone, today we will introduce to you some treatment methods for ovarian cancer. We hope that our efforts can be helpful to you.

(I) Treatment principles: Ovarian malignant tumors are treated mainly with surgery, supplemented by radiotherapy, chemotherapy, traditional Chinese medicine and other comprehensive treatments.

(II) Surgical treatment During surgery, detailed exploration should be performed first, including peritoneal lavage, palpation of pelvic and abdominal organs and pelvic retroperitoneal lymph nodes, and multiple biopsies of the diaphragm, peritoneum, and greater omentum in order to accurately stage the tumor. Surgical methods are divided into radical surgery and conservative surgery that preserves fertility. The scope of radical surgery includes bilateral adnexa, uterine omentum, appendectomy, and pelvic and retroperitoneal lymph node dissection. For patients with extensive pelvic tumor implantation and metastasis, tumor cell reduction surgery is recommended as much as possible. Williams et al. reported that the complete remission rate of postoperative chemotherapy in patients with complete surgical resection was 83%. The complete remission rate of postoperative chemotherapy in patients with basically complete resection (residual tumor diameter <2 cm) was 59%, and the complete remission rate of postoperative chemotherapy in patients with partial resection (residual tumor diameter >2 cm) was 42%. Therefore, although malignant germ cell tumors are sensitive to combined chemotherapy, removing the tumor as cleanly as possible during surgery is still the key to successful treatment.

(III) Chemotherapy: Since ovarian tumors spread very early, surgery is not enough to remove the lesions in most cases, and the effect and application of radiotherapy are also very limited. Therefore, systemic chemotherapy is an important auxiliary treatment method. After chemotherapy, the tumors of some advanced patients can be reduced, creating favorable conditions for reoperation.

There is no unified chemotherapy regimen for the treatment of malignant ovarian tumors. The principles are: ① Intermittent use of high doses and continuous use of small doses are preferred; the former means taking the drug for about one week per course of treatment and taking an interval of about 3 to 4 weeks, which can not only achieve effective anti-tumor effects but also help the body eliminate toxicity and restore immune function. ② Combination chemotherapy is more effective than single chemotherapy: in modern times, there is a trend towards combination therapy, but it should be noted that the toxicity of combined chemotherapy is more severe. ③ Selecting sensitive chemotherapy drugs based on drug sensitivity tests can prolong the patient's survival time. ④ Formulate different chemotherapy regimens according to tissue types. Each course of the above regimens is generally 3 to 4 weeks apart. The specific situation should be determined based on the patient's physical reaction, blood picture, liver and kidney function, etc. At least 4 to 6 courses of medication are required. Patients with advanced or insensitive tumors should have more courses of chemotherapy, generally 8 to 10 courses in the first year and reduced to 3 to 4 courses in the second year.

(IV) Radioimmunotherapy: The radiosensitivity of ovarian malignant tumors varies greatly. Endodermal sinus tumor of the ovary, immature teratoma, embryonal carcinoma is the least sensitive, epithelial ovarian cancer and granulosa cell carcinoma are moderately sensitive, dysgerminoma is the most sensitive, and radiotherapy after surgery can control ovarian cancer. Since ovarian cancer metastasizes to the abdominal cavity early, the irradiation range includes the abdominal cavity and pelvic cavity, liver and kidney areas, and they are protected to avoid radiation damage. The radiation dose for the whole abdominal cavity is 3000cGY~5000cGY/6~8 weeks.

Internal irradiation refers to the injection of gold (198AU) or phosphorus (32P) into the abdominal cavity, which can make the abdominal surface reach a dose that is difficult to reach with external irradiation. Due to its limited penetration, it can be used to treat superficial metastatic tumors under microscopy or stage I tumors that rupture during surgery to improve the five-year survival rate. The disadvantage is that the abdominal cavity must be free of adhesions to ensure that the radioactive isotopes are evenly distributed, otherwise it may cause intestinal damage and cause serious consequences. Generally, the amount of 198AU is 120-150 millicuries, and the amount of 32P is 10-20 millicuries.

The above is some knowledge about ovarian cancer that we have prepared for you today. I hope it will be helpful to you. If you have any other needs, you can also consult our online consulting experts of Feihua Health Network. We are always here to answer your questions. Feihua Health Network is always by your side and cares about your health issues! Feihua Health Network wishes you good health!

Ovarian cancer: http://www..com.cn/zhongliu/nc/